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The purpose of the study was to investigate the effects of expression of a range of genes involved in apoptosis on outcome in bladder
cancer. Immunohistochemistry was used to examine expression of BCL2, BAX, P53, CD40 and CD40L in archival tissues of patients
included in various treatment trials for transitional cell carcinoma (TCC) of the bladder. Data were collected on 94 patients who first
presented with either invasive or superficial bladder cancer. Median follow-up for alive patients was 83 months (m) (range 12–
195m). Median survival was 80m (95% CI¼56–128m). Median survivals for the various markers were as follows: BAX-positive
patients 110m vs BAX-negative patients18m (P¼0.0002); CD40L-positive patients 95m vs CD40L-negative patients 45m
(P¼0.04); BCL2-positive patients 44m and BCL2-negative patients 74m, (P¼0.64); CD40-positive patients 110m and CD40
negative patients 45m (P¼0.12); and P53 positive patients 80m and P53 negative patients 45m (P¼0.58). In conclusion, it was seen
that overexpressions of BAX and CD40L are prognostic of better survival in TCC of the bladder. Our results also raise the possibility
of the future development of CD40- and CD40 ligand-based immunotherapy for bladder cancer. This study links proapoptotic and
antiapoptotic markers to overall survival.
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Bladder cancer will be diagnosed in more than 54000 people
this year in USA, and over 12000 will die of the disease (ASCO
online). Bladder cancer, with 12730 new cases in 1997, is the
fifth commonest cause of cancer in the UK (Cancer Research
UK Fact Sheet). Approximately 20% of newly diagnosed cases
are invasive and, in this group, prognosis is poor with only
60% of T2 and 40% of T3 patients surviving 5 years. Patients
with more advanced or nodal disease do significantly worse;
median survival with metastatic disease for those patients
fit enough to enter trials is approximately 13 months (m).
Management of locally advanced disease is by surgery or radio-
therapy, both of which have significant drawbacks. Neoadjuvant
and adjuvant chemotherapy have been tested extensively
but to date this approach has not had a significant impact on
overall survival (Frieha et al, 1996; Malmstrom et al, 1996;
Stockle et al, 1996; International Collaboration of Trialists, 1999).
Cisplatinum-based combination chemotherapy forms the
mainstay of therapy for relapsed or metastatic disease with
response rates of up to 60–70% reported, but few long-term
survivors. Intravesical and systemic chemotherapy are limited
in their efficacy in the treatment of bladder cancer patients as
they are unable to induce apoptosis in bladder tumour cells.
Understanding the apoptotic signals and the cascade of
reactions that give prosurvival signals will go a long way in
refining the treatments and will help in future to individualise
cancer therapies.
We studied a range of molecular markers to define their roles
and their association with other markers to define targets against
which we can target appropriate therapies.
CD40 is a 48kDa membrane glycoprotein of the tumour necrosis
factor receptor (TNFR)/nerve growth factor superfamily, and is
expressed on the surface of B lymphocytes, dendritic cells,
epithelial and haemopoietic stem cells (Lee et al, 1997), and
various tumours. It was first described in 1985 as a bladder tumour
antigen (Banchereau et al, 1994) but this was largely overlooked
when subsequent investigation revealed its pivotal role in B-cell
function, where ligation with CD40 ligand (CD40L or CD154)
expressed on activated T-helper cells stimulates cell maturation,
proliferation and immunoglobulin class switching. Despite its role
as a promoter of B-cell growth, it has been previously shown that,
in common with other members of the TNFR family, CD40
stimulation sensitises carcinoma cells in vitro to apoptosis induced
by various stimuli including Fas, ceramide and cytotoxic
chemotherapy (Eliopoulos et al, 1996).
CD40 ligand (CD40L), also known as CD154, functions as the
natural ligand for CD40 (Spriggs et al, 1992; Armitage et al, 1992).
It is expressed primarily by on the surface-activated T lymphocytes
(Armitage et al, 1992) but has also been found on activated T
platelets (Henn et al, 1998). Interactions between CD40 and CD40L
provide critical costimulatory signals that trigger T-lymphocyte
expansion (Grewal et al, 1998).
We have previously demonstrated that quantification of the
antiapoptotic protein BCL2 in patients undergoing neoadjuvant
chemotherapy plus radiotherapy for advanced bladder cancer may
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sidentify patients who might benefit from neoadjuvant chemother-
apy (Cooke et al, 2000). The BCL2 oncoprotein inhibits apoptosis
and is overexpressed by many tumours including breast (Helle-
mans et al, 1995), colon (Bronner et al, 1995), prostate (Krajewska
et al, 1996) and tumours of the head and neck (Gallo et al, 1999).
By virtue of its biological activity, it may be associated with a poor
prognosis, with resistance to current treatment modalities includ-
ing radiotherapy, for example, in cervical (Harima et al, 1998) and
prostate cancer (Apakama et al, 1996). The data available to date,
describing the role played by BCL2 in transitional cell carcinoma
(TCC) of the bladder, have been both limited and conflicting, with
some studies showing an association with a lower tumour grade
(King et al, 1996) and less aggressive phenotype (Shiina et al,
1996). Others have shown the reverse, with expression being
greater in higher-stage and higher-grade tumours, resulting in
increased frequency of disease recurrence and higher disease
progression rates, leading to shortened survival (Ye et al, 1998;
Pollack et al, 1997; Kong et al, 1998). It is likely that these
conflicting results arise because of different interactions between
the various treatment modalities and apoptotic pathways. Many of
the effects of BCL2 depend on its ratio to BAX as well as on its
absolute level. The proapoptotic BH-123 proteins share three of the
BCL2 homology (BH) domains with the antiapoptotic proteins and
include BAX, BAK, and BOK. BAX plays a central role in regulation
and commitment to apoptosis. In order to further examine these
phenomena, we therefore set out to investigate the linked genes
BAX and BCL2 expression in the same group of patients, and to
examine whether these discrepant results are explained by
variations in other genes involved in the same pathways.
We therefore proceeded with immunohistochemical analysis of
these anti-apoptotic and pro-apoptotic genes to look for correla-
tion between themselves and the effects of their expression on
clinical outcome and survival. We report the expression of
antiapoptotic BCL2, proapoptotic BAX, CD40, CD40L and
accumulation of P53 in a series of patients with transitional cell
carcinoma of the bladder.
MATERIALS AND METHODS
Expression of genes was carried by immunohistochemical analysis
of the paraffin tissue archive. The tissue collection and the study
had full local research ethics approval. Ninety-four patients with
TCC of the bladder were identified from hospital records (74
males, 20 females, median age 67 years, range 32–89 years). Of
these, 45 had noninvasive tumours and were included in two
clinical trials for primary and recurrent Ta and T1 tumours, and 49
had invasive tumours, of which 26 patients were treated in a pilot
study of chemoradiation in muscle-invasive bladder cancer
(Hussain et al, 2001) and 23 patients were treated in a radiotherapy
study examining the role of neoadjuvant cisplatin for muscle-
invasive tumours (Wallace et al, 1991). Histological classification
of the patients’ tumours was obtained from the original hospital/
trial pathology records and was according to the Union
Internationale Contre le Cancer (UICC) TNM system, 1997. The
archived tissue specimens were retrieved, all of which had been
routinely fixed in 10% saline-buffered formalin and embedded in
paraffin wax. One representative tissue block was chosen for each
patient on the basis of gross specimen morphology, and serial 5mm
sections were cut from it and mounted onto microscope slides.
One section from each specimen was then immunostained for
BCL2, BAX, CD40, CD40L and P53, plus a specimen for routine
haematoxylin and eosin staining.
Staining procedure
Tissue sections were deparaffinised in xylene, washed in alcohol
and rehydrated in 0.05 M pH 7.6 phosphate-buffered saline (PBS).
Antigen retrieval was performed in a 700W microwave oven in
0.01 M pH 5.8 citrate buffer solution for 30min as optimised in
preliminary studies. The sections were cooled to room temperature
in PBS, the primary antibody applied and incubated in a moist
chamber at room temperature for 1h. The primary antibodies and
concentrations used were as shown in Table 1. The secondary
staining and tertiary staining was performed using DAKO strept
ABC complex (DAKO Ltd, Cambridgeshire, UK). Secondary and
tertiary antibodies were applied and incubated in a moist chamber
at room temperature for 30min. Sections were counterstained in
Mayer’s haematoxylin and mounted in aqueous mountant
(Shandon, UK). Sections of tonsil were used as positive control
for each staining run. Substituting primary antibody with PBS
created negative controls. Tissue lymphocytes acted as an
additional internal control for the CD40- and BCL2-stained
sections. Evaluation of immunostaining (Table 2) was performed
on two separate occasions by one observer (SAH) and once by a
pathologist (RG), both of whom were blinded to any other data.
The whole of each section was subjectively assessed under light
microscopy. There was one score for the strength of staining
(absent, weak or strong, respectively, as compared with the
positive controls) and one score for the percentage of tumour
stained (absent, focal/patchy or diffuse). Staining of mitotic figures
was ignored and only nuclear staining was regarded as positive for
P53. Sections where intra or interobserver error occurred for either
of the scores were reviewed again by a pathologist (RG or MM) and
assigned a score that dictated which of the two original scores was
recorded. In the event of all three pairs of scores differing, a
consensus score was agreed upon after examination under a
multiheaded microscope. Tumours were classified into five
patterns of expression: tumour negative; weak diffuse (WD); weak
focal (WF); strong diffuse (SD); or strong focal (SF). Of the 94
specimens, satisfactory staining was achieved in 86 cases (91.5%).
In cases where staining was not optimal for evaluation, they were
Table 1 Antibodies used
Antibody Code Source Dilution Supplier
BCL2 (C-2):Sc-7382 Mouse monoclonal antibody 1:10 Santa Cruz, CA, USA
BAX P-19:Sc-526 Rabbit purified polyclonal antibody 1:20 Santa Cruz, CA, USA
CD40 (N-16):Sc-974 Rabbit polyclonal antibody 1:100 Santa Cruz, CA, USA
CD40L (C-20):Sc-978 Rabbit polyclonal antibody 1:100 Santa Cruz, CA, USA
P53 (Bp 53-12):Sc-263 Mouse monoclonal antibody 1:20 Santa Cruz, CA, USA
Table 2 Evaluation of staining
BCL2, BAX, CD40, CD40L P53
Diffuse Confluent positivity >30% of nuclei
Focal Nonconfluent islands of positivity o30% of nuclei
Strong Intensely brown Intensely brown
Weak Weakly brown Weakly brown
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tissue was identified with no evidence of transitional cell
carcinoma. In the remaining 81 out of the 94 (86%) cases stained
for BAX, 83 out of the 94 (88%) for BCL2, 79 out of the 94 (84%)
for CD40, 79 out of the 94 (84%) for CD40L and 78 out of the 94
(83%) for P53 contained foci of malignancy.
Statistical methods
Intercorrelations between the laboratory measures were explored
by use of Fisher’s exact tests and Correspondence Analysis
(Greenacre, 1984), an exploratory technique used to analyse
multi-way tables. Survival times were calculated as the date of
primary tumour diagnosis to date of death, or date of censor if
alive. Survival curves were constructed using the method of Kaplan
and Meier (1958), and the log-rank test (Peto et al, 1977) was used
to assess any differences between patient and tumour character-
istics. Cox proportional hazards analysis (Cox, 1972) was also
performed, using a 5% entry and exit criterion, to determine
important independent prognostic factors of survival.
Statistical analysis was carried out independently using SAS
statistical software (SAS Institute, Cary, NC, USA).
RESULTS
Intercorrelation between laboratory measures
Fisher’s exact tests showed the BCL2 marker to be independent of
all others (P40.05). P53 was also shown to be independent of all
other markers, except a borderline dependence with BAX
(P¼0.04). BAX, CD40 and CD40L were all significantly associated
with each other (Pp0.05). Correspondence analysis confirmed the
above by showing a separate tight clustering of the expression
levels of BAX, CD40 and CD40L, which were also separate from the
two distinct levels of both BCL2 and P53. This indicates that BAX,
CD40 and CD40L vary together and thus explain similar
characteristics about patients. BCL2 and P53 are shown as
individual markers dissimilar to all others thus measuring
different things.
Analysis of the individual subgroups (negative, WF, WD, SF,
SD) demonstrated statistically significant interactions between all
subgroups of expression for BAX, with strong positivity with a
diffuse pattern of BAX expression as an independent prognostic
marker of survival (P¼0.0001). However, since focality of
expression was a relatively subjective observation dependent on
variable factors such as the even distribution of antigen at the time
of staining, we grouped the results into better definable groups
based only on the strength of staining. Despite ignoring the pattern
of staining, BAX remained an independent marker of prognostic
significance of survival (P¼0.0002). Patients with tumours over-
expressing BAX had a median survival of 110m as against a group
of patients with weak expression or no expression of BAX who had
a median survival of 18m (Figure 1). Similar considerations
applied to CD40L and so, for practical purposes, cases were then
grouped as either positive (strong) for (SF or SD) expression or
negative (weak) for (negative, WF or WD) expression, as this gave
the most easily clinically applicable scoring system. There were no
significant differences seen for expression of CD40, P53 or BCL2,
but the same grouping system was applied to these groups in the
interests of consistency of analysis.
The median survival for all patients from the day of diagnosis of
primary tumour was 80m. There were statistically significant
effects according to expression levels of BAX (110m vs 18m,
P¼0.0002) (Figure 1) and CD40L (95m vs 45m, P¼0.04), with
overexpression of CD40L leading to better survival (Figure 2). For
CD40, median survival by subgroup was positive 110m and
negative 45m, P¼0.12 (Figure 3); for BCL2, positive 44m and
negative 74m, P¼0.64 (Figure 4). For P53, the results were again
not significant with median survivals of 80m for positive and 45m
for negative P¼0.58 (Figure 5). As would be expected, there were
significant associations between tumour stage (Ta/1 vs T2 vs T3 vs
T4 with median survivals of 128, 23, 19 and 27m, respectively,
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Figure 1 Survival by BAX (— strong; F weak).
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128 and 45m, respectively, P¼0.02) (Figure 7).
Cox regression on survival
Cox regression showed stage (Ta or T1 vs T2–4) to be the most
important independent prognostic factor (Po0.0001, HR¼1.77,
95% CI 1.34–2.33) and, if it is known, no other variable adds to the
accuracy of prognosis. However, if stage is unknown, BAX
(P¼0.0003, HR¼3.00, 95% CI¼1.64–5.48) and CD40L
(P¼0.04, HR¼1.99, 95% CI¼1.03–3.83) are shown to be
important prognostic markers although either of the one rules
out the need for the other. No further variables were deemed
important in survival prognosis.
DISCUSSION
A fundamental difficulty in the understanding, prevention and
treatment of cancer is that the currently recognised disease classes
are each really a collection of diseases having significant features in
common (e. g. the organ where the tumour arose), but also many
features that distinguish them. The diversity within most disease
categories is reflected in a diversity of responses to specific
therapeutic regimens. Numerous studies indicate that this clinical
heterogeneity reflects underlying molecular heterogeneity, and
therefore we have begun to use gene expression measurements to
build a higher resolution and more clinically relevant taxonomy of
human tumours. Our study analysed a large collection of archived
tumour samples, where the treatment history and outcomes of the
patients were well documented, and reveals interesting associa-
tions with a group of genes involved in regulation of apoptosis.
The CD40 receptor is expressed in many immune cell types and
is known to play a central role in both humoral and T-cell-
mediated immunity, a subject of intense research interest in recent
years. It is also expressed on a variety of carcinomas and may
therefore be of biological significance in the development and
treatment of cancer (Young et al, 1998; Gallagher et al, 2002). Our
group has previously examined expression of CD40 by immuno-
histochemistry in TCC of the bladder and the correlation with
known prognostic markers and clinical outcome (Cooke et al,
1999). Seventy-eight percent of the tumours were CD40 positive,
with a highly significant association with both lower stage and
lower grade (Po0.001). CD40 expression was not found to be an
independent prognostic marker of survival in our previous study.
We extended these previous observations by additionally assessing
the expression of CD40L and P53 in this group of patients to
further investigate their role as prognostic markers.
In this study, we were able to demonstrate expression of CD40L
in bladder tumour tissue (Figure 8), the first such demonstration
in nonlymphoid tissue. Furthermore, overexpression of CD40L was
significantly associated with improved outcome (Figure 2).
Although overexpression of CD40 was not prognostically sig-
nificant at the 5% level (P¼0.12, Figure 3), it was significantly
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sFigure 8 Pathology image. (A) Magnification 40 objective, CD40 shows diffuse strong cytoplasmic staining in myo invasive transitional cell carcinoma.
(B) 40 objective, CD40L antibodies stains neoplastic cells strongly positive. (C) 40 objective, BAX shows strong positive staining of the surface in this
transitional cell carcinoma. (D) 20 objective, shows myo invasive islands stain strongly positive for BAX. (E) 20 objective, weak and focal positivity of
BCL2, few tissue lymphocytes serve as positive internal controls. (F) 20 objective, strong diffuse nuclear positivity is seen on p53 staining.
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sassociated with expression of CD40L by Fisher’s exact test,
suggesting that both ligand and receptor are likely to be necessary
for biological effect.
The BCL2 oncoprotein inhibits apoptosis. As a complex network
of regulatory pathways control apoptosis and the sensitivity of
apoptosis is the result of the balance between pro- and
antiapoptotic proteins, we set out to examine other apoptosis-
regulating proteins. There is increasing evidence from other
tumour sites showing the role of BAX as a prognostic marker. In
ovarian cancer, it was shown that high BAX expression was
associated with significant improvement of the percentage of
complete remissions after first-line chemotherapy with Paclitaxel
and a platinum analogue. Survival was also high in groups with
high BAX expression (Tai et al, 1998). In patients with breast
cancer, loss of BAX immunostaining was associated with a
decreased response to chemotherapy and shorter survival (Kra-
jewski et al, 1995). In diffuse aggressive non-Hodgkin’s lymphoma,
reduced BAX expression was associated with a lower 8-year
survival (Gascoyne et al, 1997). BAX plays a central role in
regulation and commitment to programmed cell death. BAX
counteracts the apoptosis-preventing effect of BCL2 and may
directly induce apoptosis (Xiang et al, 1996; Zha and Reed, 1997).
The proapoptotic BAX is located in the outer mitochondrial
membrane (Schlesinger et al, 1997). BAX overexpression induces
mitochondrial permeability transition, which leads to the release of
cytochrome c (Pastorino et al, 1998). BAX-negative tumours,
therefore, may be less susceptible to apoptosis. BAX/P53 pathway
analysis in colorectal cancer with hepatic metastases showed that
patients with high BAX protein expression in resected liver lesions
had a median survival of 53.6m compared with 35.4m for patients
with low BAX expression (Po0.05). Low BAX expression was an
independent negative prognostic marker in multivariate regression
analysis for all patients independent of the P53 status (Sturm et al,
1999). In our study, overexpression of BAX was associated with a
favourable outcome (Figure 1). Expression of BAX was shown to
be independent of both BCL2 and P53 both by Fisher’s exact test
and by Correspondence Analysis, suggesting that it relates to
different aspects of the biology of the tumour. On the other hand,
BAX expression was associated with expression of CD40 and
CD40L, suggesting that all three are linked in their behaviours in
this tumour type.
Our results also reveal a significant association between
overexpression of CD40 ligand and survival. CD40 ligation thus
could be used to sensitise a tumour to conventional treatment
modalities such as chemo- or radiotherapy and additionally with a
potential for stimulating natural immunity against solid tumours
in the manner, which has already been seen in other malignancies
both in vitro and in vivo (Eliopoulos et al, 1996; Bergamo et al,
1997; Dilloo et al, 1997; Kikuchi and Crystal, 1999). There is
evidence to support the notion of CD40 ligation-induced apoptosis
as a mechanism for eliminating neoplastically transformed
urothelial cells (Bugajska et al, 2002). A phase I study of
recombinant Human CD40L in patients with advanced solid
tumours or intermediate- or high-grade non-Hodgkin’s lymphoma
demonstrated encouraging antitumour activity, including a long-
term complete remission (Vonderheide et al, 2001). Therapeutic
use of CD40L in future will be incorporated into radical treatment
of bladder cancer to get a clear picture of their efficacy and
toxicity. We intend to use more sophisticated techniques including
microarrays in a group of patients undergoing treatment in a
randomised setting, with the ultimate hope of being able to further
sub-classify bladder tumours into clinically homogenous groups.
Expression of these genes was seen across the range of grades
and stages of disease. Once these are stratified into various stages
and grades, the number of cases decreases and the statistical power
to discriminate is lost. It would be very interesting to follow
patients with low-grade tumours at diagnosis in a randomised
clinical trial setting with Bax, Bcl-2, CD40 and CD40L mapping and
note whether overexpression or underexpression of these markers
by immunohistochemistry predates the aggressive clinical beha-
viour and therefore indicates a point of therapeutic intervention.
In conclusion, this is the first study that has examined
expression of BAX in all stages of transitional cell carcinoma of
the bladder. We believe that analysis of molecular markers such as
BAX, BCL2, CD40 and CD40L may prove valuable in identifying
patients with poor prognosis bladder cancers who may benefit
from aggressive treatment and this should be considered in future
trial design. Bladder is a particularly attractive model to study, as it
provides a conveniently isolated field to test new therapies, and
repeated endoscopic assessment and tissue biopsies are possible
during the course of treatment and post-treatment to evaluate the
response to the therapy. Furthermore, the disease itself, if
advanced to muscle invasion, carries a poor outlook as seen in
our series, with median survival dropping from 128m for stage Ta
or T1, to 23m for stage T2, 19m for stage T3 and 27m for stage T4
with a P-value of 0.0001 (Figure 6). This also strengthens the
statement that Ta, T1 and invasive bladder cancers are two
different entities with remarkably different clinical outcomes.
Endoscopic assessment of bladder tissue at various time points
in organ preservation strategies will also help us to understand and
answer many aspects of programmed cell death. All forms of
cancer therapy risk selecting for resistance, a problem com-
pounded by plasticity of the tumour cell genome (Green and Evan,
2002). The most effective strategy will definitely be a combination
treatment attacking several targets specific to cancer. The
evolution of such sophisticated forms of treatment will undoubt-
edly proceed by a process that employs both rational and empiric
approaches. Our study generates a hypothesis linking proapoptotic
and antiapoptotic markers to overall survival and needs to be
tested robustly in a randomised clinical trial setting.
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